Boston Scientific price target raised to $58 from $53 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on Boston Scientific to $58 from $53 and keeps a Buy rating on the shares. The analyst said we remain positive on the accelerating organic revenue growth, forthcoming product launches, and continued margin expansion.